India's Richest People 2026 edition · 1 director · Source: Hurun India
- #872 Varinder Gupta & family ₹3,400 Cr
Market Cap
₹5,409 Cr
IOLCP · NSE
Share Price
₹202.95
+10.13% today
Revenue
₹2,319 Cr
FY 2025-26 · +11.5% YoY
EBITDA
₹258 Cr
Margin 11.1%
Net Profit
₹147 Cr
FY 2025-26 · +44.8% YoY
P/E (TTM)
25.4x
P/B 2.8x
ROE
7.9%
ROCE 10.6%
Debt / Equity
0.07
Interest cover 8.2x
About Iol Chemicals and Pharmaceuticals Limited
Data last updated:
Iol Chemicals and Pharmaceuticals Limited is a public limited company based in Barnala, Punjab, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 29 September 1986 and has been in existence for over 40 years.
Its director Varinder Gupta and family are #872 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Chandigarh, under CIN L24116PB1986PLC007030. Its GSTIN is 03AABCI1842A1ZF (Punjab). The company holds 5 GST registrations, of which 3 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 524164 and NSE: IOLCP.
The company has an authorised share capital of ₹80 Cr and a paid-up capital of ₹58.71 Cr. It was formerly known as Industrial Organics Limited and Trident Alco-Chem Limited. It is led by directors including Varinder Gupta (Managing Director) and Vikas Gupta (Whole-Time Director).
Its last annual general meeting (AGM) was held on 22 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Village & Post Office – Handiaya Fatehgarh Chhanna Road Tehsil & District, Barnala, Punjab, India – 148107.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹2,319.06 Cr, a growth of 11.5% compared to the previous year. For the same year it recorded a net profit of ₹146.58 Cr (net margin 6.3%) and EBITDA of ₹257.76 Cr (EBITDA margin 11.1%). The net worth stands at ₹1,798.55 Cr (up 6.6% YoY). Total assets are valued at ₹1,944.93 Cr (up 7.4% YoY).
The company has about 2,778 employees on its provident fund (EPFO) records. Its group structure includes 3 subsidiaries.
The company is associated with 1 brand: IOLCP. As per MCA filings, the company has open charges of ₹700 Cr and satisfied charges of ₹1,487.01 Cr on record. Court records list 76 cases involving the company, including 31 filed by the company and 46 filed against it; 14 cases are pending. The company has 105 deals on record (70 market trades, 24 funding rounds, 11 secondary share transfers), with disclosed funding of ₹238.16 Cr; the latest was in July 2026. Its 3 peer companies in the Chemicals industry (API Manufacturers, Pharmaceuticals, Specialty Chemicals), with the same principal business activity (manufacture of chemicals and chemical products) are compared by revenue, 2 larger and 1 smaller; the largest is Fine Organic Industries Limited with revenue of ₹2,366.75 Cr. The company has 11 MSME Form 1 returns on record between 2019 and 2024, listing 280 overdue payments to 65 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website iolcp.com.
Company details
CIN L24116PB1986PLC007030
Registration Number 007030
Incorporation Date 29 September 1986
ROC Chandigarh
Listing Status Listed - Listed on NSE (IOLCP); Listed on BSE (524164)
Company Status Active
Date of Last AGM 22 August 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
Name history
Iol Chemicals and Pharmaceuticals has undergone 2 name changes throughout its history. The company was previously known as Industrial Organics Limited, and Trident Alco-Chem Limited. The current legal name is Iol Chemicals And Pharmaceuticals Limited.
| Company Name | Status |
|---|---|
| Iol Chemicals and Pharmaceuticals Limited | Current |
| Industrial Organics Limited | Previous |
| Trident Alco-Chem Limited | Previous |
CIN history
Iol Chemicals and Pharmaceuticals has one previous CIN (Corporate Identification Number): U24116PB1986PLC007030. The current CIN is L24116PB1986PLC007030, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24116PB1986PLC007030 | Current |
| U24116PB1986PLC007030 | Previous |
Key People
Varinder Gupta Managing Director Vikas Gupta Whole-Time Director Kushal Kumar Rana Whole-Time Director Recognitions & Rankings of Iol Chemicals and Pharmaceuticals
Contact details
Iol Chemicals and Pharmaceuticals Limited's registered office is in Barnala, Punjab. Its website is iolcp.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressVillage & Post Office – Handiaya Fatehgarh Chhanna Road Tehsil & District, Barnala, Punjab, India – 148107
- IndustryPharma, API Manufacturers
To see the full contact details of Iol Chemicals and Pharmaceuticals Limited, buy the company report.
Comprehensive company report
Iol Chemicals and Pharmaceuticals Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Iol Chemicals and Pharmaceuticals is manufacturing. In detail, this covers manufacture of chemicals and chemical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | 20 | Manufacture of chemicals and chemical products |
To see the full business activity and turnover split of Iol Chemicals and Pharmaceuticals Limited, buy the company report.
Financials of Iol Chemicals and Pharmaceuticals Limited
FY 2025-26 filings availableIol Chemicals and Pharmaceuticals Limited reported revenue of ₹2,319.06 Cr (up 11.5% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹2,319 Cr
+11.5% YoY
EBITDA
₹258 Cr
+27.4% YoY
Profit After Tax
₹147 Cr
+44.8% YoY
Net Worth
₹1,799 Cr
+6.6% YoY
Total Assets
₹1,945 Cr
+7.4% YoY
Total Debt
₹135 Cr
+15.7% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 2,319 | 2,079 | 2,133 | 2,217 | 2,184 |
| Revenue growth | +11.5% | -2.5% | -3.8% | +1.5% | - |
| EBITDA | 258 | 202 | 231 | 226 | 244 |
| EBITDA margin | +11.1% | +9.7% | +10.8% | +10.2% | +11.2% |
| Profit before tax | 184 | 138 | 182 | 189 | 225 |
| Net profit | 147 | 101 | 134 | 139 | 179 |
| Net profit margin | +6.3% | +4.9% | +6.3% | +6.3% | +8.2% |
| EPS (₹) | 4.69 | 3.44 | 22.90 | 23.70 | 28.56 |
| Balance sheet | |||||
| Total assets | 1,945 | 1,811 | 1,651 | 1,589 | 1,439 |
| Net worth | 1,799 | 1,688 | 1,612 | 1,508 | 1,392 |
| Total debt | 135 | 117 | 32.76 | 79.81 | 43.95 |
| Cash & bank | 198 | 208 | 143 | 21.83 | 140 |
| Net working capital | 667 | 655 | 590 | 541 | 609 |
| Cash flow | |||||
| Cash from operations | 214 | 179 | 290 | 122 | 93.05 |
| Cash from investing | (198) | (154) | (191) | (120) | (121) |
| Cash from financing | (29.03) | 46.04 | (92.50) | (4.11) | (1.64) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 756 | 619 | 580 | 568 | 552 | 528 | 523 | 526 |
| Revenue growth (YoY) | +37.1% | +17.4% | +10.9% | +8.0% | +9.8% | - | - | - |
| Other income | 8.18 | 1.84 | 5.29 | 6.88 | 7.37 | 4.52 | 4.07 | 6.43 |
| EBITDA | 103 | 92.47 | 46.07 | 57.08 | 62.14 | 62.76 | 46.87 | 41.57 |
| EBITDA margin | +13.7% | +14.9% | +7.9% | +10.1% | +11.3% | +11.9% | +9.0% | +7.9% |
| Depreciation | 21.34 | 20.29 | 20.18 | 19.99 | 19.77 | 18.55 | 18.68 | 17.94 |
| Interest | 3.64 | 3.21 | 3.63 | 3.48 | 4.23 | 4.03 | 4.46 | 4.12 |
| Profit before tax | 86.69 | 70.81 | 27.55 | 40.49 | 45.51 | 44.70 | 27.80 | 25.94 |
| Tax | 22.29 | 17.65 | 6.97 | 10.52 | 11.58 | 13.28 | 7.27 | 6.79 |
| Net profit | 64.40 | 53.16 | 20.58 | 29.97 | 33.93 | 31.42 | 20.53 | 19.15 |
| EPS (₹) | 2.19 | 1.81 | 0.70 | 1.02 | 1.16 | 1.07 | 3.50 | 3.26 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 2,319 | 2,079 | 2,133 | 2,217 | 2,184 | 1,967 | 1,894 |
| Revenue growth | +11.5% | -2.5% | -3.8% | +1.5% | +11.0% | +3.8% | - |
| EBITDA | 258 | 202 | 232 | 227 | 242 | 592 | 574 |
| EBITDA margin | +11.1% | +9.7% | +10.9% | +10.2% | +11.1% | +30.1% | +30.3% |
| Profit before tax | 184 | 138 | 183 | 189 | 223 | 571 | 533 |
| Net profit | 147 | 101 | 135 | 140 | 177 | 445 | 361 |
| Net profit margin | +6.3% | +4.9% | +6.4% | +6.3% | +8.1% | +22.6% | +19.1% |
| EPS (₹) | 4.69 | 3.44 | 23.07 | 23.84 | 28.22 | 75.72 | 63.51 |
| Balance sheet | |||||||
| Total assets | 1,945 | 1,811 | 1,651 | 1,588 | 1,437 | 1,267 | 877 |
| Net worth | 1,798 | 1,687 | 1,611 | 1,507 | 1,390 | 1,260 | 814 |
| Total debt | 135 | 117 | 32.76 | 79.81 | 43.95 | 2.73 | 59.49 |
| Cash & bank | 198 | 208 | 143 | 20.90 | 138 | 365 | 155 |
| Net working capital | 667 | 655 | 590 | 540 | 607 | 719 | 451 |
| Cash flow | |||||||
| Cash from operations | 214 | 179 | 290 | 123 | 91.04 | 380 | 471 |
| Cash from investing | (198) | (154) | (191) | (119) | (121) | (317) | (184) |
| Cash from financing | (29.03) | 46.04 | (92.50) | (4.11) | (1.64) | (58.28) | (272) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 756 | 619 | 580 | 568 | 552 | 528 | 523 | 526 |
| Revenue growth (YoY) | +37.1% | +17.4% | +10.9% | +8.0% | +9.8% | - | - | - |
| Other income | 8.18 | 1.74 | 5.29 | 6.88 | 7.37 | 4.52 | 4.07 | 6.43 |
| Total expenses | 653 | 527 | 534 | 510 | 490 | 465 | 476 | 484 |
| EBITDA | 104 | 92.57 | 46.06 | 57.10 | 62.15 | 62.94 | 46.87 | 41.56 |
| EBITDA margin | +13.7% | +14.9% | +7.9% | +10.1% | +11.3% | +11.9% | +9.0% | +7.9% |
| Depreciation | 21.32 | 20.27 | 20.17 | 19.98 | 19.75 | 18.53 | 18.66 | 17.93 |
| Interest | 3.64 | 3.21 | 3.63 | 3.48 | 4.23 | 4.03 | 4.46 | 4.12 |
| Profit before tax | 86.77 | 70.83 | 27.55 | 40.52 | 45.54 | 44.90 | 27.82 | 25.94 |
| Tax | 22.29 | 17.65 | 6.97 | 10.52 | 11.58 | 13.28 | 7.27 | 6.79 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 09 Nov 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 756 | 619 | 580 | 568 | 552 | 528 | 523 | 526 |
| Revenue growth (YoY) | +37.1% | +17.4% | +10.9% | +8.0% | +9.8% | - | - | - |
| Other income | 8.18 | 1.84 | 5.29 | 6.88 | 7.37 | 4.52 | 4.07 | 6.43 |
| EBITDA | 103 | 92.47 | 46.07 | 57.08 | 62.14 | 62.76 | 46.87 | 41.57 |
| EBITDA margin | +13.7% | +14.9% | +7.9% | +10.1% | +11.3% | +11.9% | +9.0% | +7.9% |
| Depreciation | 21.34 | 20.29 | 20.18 | 19.99 | 19.77 | 18.55 | 18.68 | 17.94 |
| Interest | 3.64 | 3.21 | 3.63 | 3.48 | 4.23 | 4.03 | 4.46 | 4.12 |
| Profit before tax | 86.69 | 70.81 | 27.55 | 40.49 | 45.51 | 44.70 | 27.80 | 25.94 |
| Tax | 22.29 | 17.65 | 6.97 | 10.52 | 11.58 | 13.28 | 7.27 | 6.79 |
| Net profit | 64.40 | 53.16 | 20.58 | 29.97 | 33.93 | 31.42 | 20.53 | 19.15 |
| EPS (₹) | 2.19 | 1.81 | 0.70 | 1.02 | 1.16 | 1.07 | 3.50 | 3.26 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Revenue | 2,319 | 2,079 | 2,133 | 2,217 | 2,184 |
| Revenue growth | +11.5% | -2.5% | -3.8% | +1.5% | - |
| Other income | 21.38 | 22.41 | 30.07 | 25.61 | 32.04 |
| Total expenses | 2,061 | 1,877 | 1,902 | 1,991 | 1,940 |
| Employee cost | 248 | 217 | 201 | 168 | 141 |
| EBITDA | 258 | 202 | 231 | 226 | 244 |
| EBITDA margin | +11.1% | +9.7% | +10.8% | +10.2% | +11.2% |
| Depreciation | 80.23 | 71.99 | 62.91 | 46.16 | 43.26 |
| Interest | 14.55 | 14.76 | 16.10 | 16.47 | 8.29 |
| Profit before tax | 184 | 138 | 182 | 189 | 225 |
| Tax | 46.72 | 36.89 | 47.22 | 49.51 | 57.18 |
| Net profit | 147 | 101 | 134 | 139 | 179 |
| Net profit margin | +6.3% | +4.9% | +6.3% | +6.3% | +8.2% |
| EPS (₹) | 4.69 | 3.44 | 22.90 | 23.70 | 28.56 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Equity & liabilities | |||||
| Share capital | 58.71 | 58.71 | 58.71 | 58.71 | 58.71 |
| Reserves & surplus | 1,740 | 1,629 | 1,553 | 1,449 | 1,334 |
| Shareholders' funds (net worth) | 1,799 | 1,688 | 1,612 | 1,508 | 1,392 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 132 | 117 | 32.76 | 79.63 | 42.75 |
| Unsecured loans | 3.42 | 0.00 | 0.00 | 0.18 | 1.20 |
| Total debt | 135 | 117 | 32.76 | 79.81 | 43.95 |
| Total liabilities | 1,945 | 1,811 | 1,651 | 1,589 | 1,439 |
| Assets | |||||
| Gross block | 1,632 | 1,544 | 1,236 | 994 | 762 |
| Net block | 1,182 | 1,171 | 933 | 752 | 561 |
| Capital work in progress | 95.54 | 21.93 | 101 | 89.64 | 105 |
| Investments | 20.92 | 20.71 | 20.29 | 19.97 | 2.37 |
| Inventories | 371 | 361 | 425 | 326 | 410 |
| Sundry debtors | 603 | 514 | 471 | 505 | 470 |
| Cash & bank balances | 198 | 208 | 143 | 21.83 | 140 |
| Loans & advances | 51.56 | 65.58 | 77.93 | 65.20 | 58.77 |
| Total current assets | 1,224 | 1,148 | 1,117 | 918 | 1,078 |
| Total current liabilities | 557 | 493 | 527 | 376 | 470 |
| Net working capital | 667 | 655 | 590 | 541 | 609 |
| Total assets | 1,945 | 1,811 | 1,651 | 1,589 | 1,439 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Opening cash | 78.17 | 7.69 | 1.39 | 3.23 | 32.34 |
| Net cash from operating activities | 214 | 179 | 290 | 122 | 93.05 |
| Net cash from investing activities | (198) | (154) | (191) | (120) | (121) |
| Net cash from financing activities | (29.03) | 46.04 | (92.50) | (4.11) | (1.64) |
| Net change in cash | (12.82) | 70.48 | 6.30 | (1.84) | (29.11) |
| Closing cash | 198 | 208 | 143 | 21.83 | 140 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Growth | |||||
| Sales growth | +11.5% | -2.5% | -3.8% | +1.5% | - |
| EBITDA growth | +27.4% | -12.3% | +2.2% | -7.7% | - |
| PBT growth | +33.6% | -24.1% | -3.7% | -16.1% | +9997.0% |
| Net income growth | +44.8% | -24.7% | -3.6% | -22.0% | - |
| Revenue CAGR (3Y) | +1.5% | -1.6% | - | - | - |
| EBITDA CAGR (3Y) | +4.5% | -6.1% | - | - | - |
| Profitability & leverage | |||||
| Net income margin | +5.9% | +4.9% | +6.3% | +6.3% | +7.7% |
| Return on capital employed | +10.6% | +8.8% | +12.2% | +13.5% | +16.2% |
| Return on net worth | +7.9% | +6.1% | +8.6% | +9.6% | +12.0% |
| Debt / equity | 0.07 | 0.05 | 0.04 | 0.04 | 0.03 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 8.20 | 11.33 | 9.60 | 9.17 | 4.12 |
| Efficiency & per share | |||||
| Fixed asset turnover | 1.46 | 1.50 | 1.91 | 2.52 | 2.87 |
| Inventory turnover | 6.34 | 5.29 | 5.68 | 6.03 | 5.33 |
| Debtors turnover | 4.15 | 4.22 | 4.37 | 4.55 | 4.65 |
| EPS (₹) | 4.69 | 3.44 | 22.90 | 23.70 | 28.56 |
| Dividend per share (₹) | 1.00 | 0.80 | 5.00 | 4.00 | 4.00 |
| Book value per share (₹) | 61.27 | 57.49 | 274.49 | 256.81 | 237.15 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 756 | 619 | 580 | 568 | 552 | 528 | 523 | 526 |
| Revenue growth (YoY) | +37.1% | +17.4% | +10.9% | +8.0% | +9.8% | - | - | - |
| Other income | 8.18 | 1.74 | 5.29 | 6.88 | 7.37 | 4.52 | 4.07 | 6.43 |
| Total expenses | 653 | 527 | 534 | 510 | 490 | 465 | 476 | 484 |
| EBITDA | 104 | 92.57 | 46.06 | 57.10 | 62.15 | 62.94 | 46.87 | 41.56 |
| EBITDA margin | +13.7% | +14.9% | +7.9% | +10.1% | +11.3% | +11.9% | +9.0% | +7.9% |
| Depreciation | 21.32 | 20.27 | 20.17 | 19.98 | 19.75 | 18.53 | 18.66 | 17.93 |
| Interest | 3.64 | 3.21 | 3.63 | 3.48 | 4.23 | 4.03 | 4.46 | 4.12 |
| Profit before tax | 86.77 | 70.83 | 27.55 | 40.52 | 45.54 | 44.90 | 27.82 | 25.94 |
| Tax | 22.29 | 17.65 | 6.97 | 10.52 | 11.58 | 13.28 | 7.27 | 6.79 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,319 | 2,079 | 2,133 | 2,217 | 2,184 | 1,967 | 1,894 |
| Revenue growth | +11.5% | -2.5% | -3.8% | +1.5% | +11.0% | +3.8% | - |
| Other income | 21.28 | 22.40 | 30.07 | 25.57 | 32.04 | 24.30 | 16.02 |
| Total expenses | 2,061 | 1,877 | 1,901 | 1,991 | 1,942 | 1,375 | 1,321 |
| Employee cost | 248 | 217 | 201 | 168 | 141 | 116 | 97.20 |
| EBITDA | 258 | 202 | 232 | 227 | 242 | 592 | 574 |
| EBITDA margin | +11.1% | +9.7% | +10.9% | +10.2% | +11.1% | +30.1% | +30.3% |
| Depreciation | 80.17 | 71.92 | 62.85 | 46.13 | 43.26 | 38.92 | 35.73 |
| Interest | 14.55 | 14.76 | 16.10 | 16.47 | 8.29 | 5.83 | 20.93 |
| Profit before tax | 184 | 138 | 183 | 189 | 223 | 571 | 533 |
| Tax | 46.72 | 36.89 | 47.22 | 49.51 | 57.18 | 127 | 172 |
| Net profit | 147 | 101 | 135 | 140 | 177 | 445 | 361 |
| Net profit margin | +6.3% | +4.9% | +6.4% | +6.3% | +8.1% | +22.6% | +19.1% |
| EPS (₹) | 4.69 | 3.44 | 23.07 | 23.84 | 28.22 | 75.72 | 63.51 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 58.71 | 58.71 | 58.71 | 58.71 | 58.71 | 58.71 | 56.89 |
| Reserves & surplus | 1,740 | 1,629 | 1,553 | 1,448 | 1,332 | 1,202 | 747 |
| Shareholders' funds (net worth) | 1,798 | 1,687 | 1,611 | 1,507 | 1,390 | 1,260 | 814 |
| Secured loans | 0.00 | 117 | 32.76 | 79.63 | 42.75 | 0.00 | 55.99 |
| Unsecured loans | 135 | 0.00 | 0.00 | 0.18 | 1.20 | 2.73 | 3.50 |
| Total debt | 135 | 117 | 32.76 | 79.81 | 43.95 | 2.73 | 59.49 |
| Total liabilities | 1,945 | 1,811 | 1,651 | 1,588 | 1,437 | 1,267 | 877 |
| Assets | |||||||
| Gross block | 1,632 | 1,544 | 1,236 | 995 | 762 | 677 | 597 |
| Net block | 1,181 | 1,170 | 933 | 751 | 561 | 512 | 469 |
| Capital work in progress | 95.54 | 21.93 | 101 | 89.64 | 105 | 48.27 | 19.19 |
| Investments | 21.12 | 21.01 | 20.59 | 20.27 | 2.47 | 1.22 | 0.05 |
| Inventories | 371 | 361 | 425 | 326 | 410 | 295 | 188 |
| Sundry debtors | 603 | 514 | 471 | 505 | 470 | 300 | 272 |
| Cash & bank balances | 198 | 208 | 143 | 20.90 | 138 | 365 | 155 |
| Loans & advances | 51.55 | 65.57 | 77.91 | 64.81 | 58.77 | 48.48 | 56.16 |
| Total current assets | 1,224 | 1,148 | 1,117 | 917 | 1,076 | 1,009 | 671 |
| Total current liabilities | 557 | 493 | 527 | 376 | 470 | 290 | 220 |
| Net working capital | 667 | 655 | 590 | 540 | 607 | 719 | 451 |
| Total assets | 1,945 | 1,811 | 1,651 | 1,588 | 1,437 | 1,267 | 877 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 78.02 | 7.53 | 0.96 | 1.12 | 32.34 | 28.09 | 13.41 |
| Net cash from operating activities | 214 | 179 | 290 | 123 | 91.04 | 380 | 471 |
| Net cash from investing activities | (198) | (154) | (191) | (119) | (121) | (317) | (184) |
| Net cash from financing activities | (29.03) | 46.04 | (92.50) | (4.11) | (1.64) | (58.28) | (272) |
| Net change in cash | (12.73) | 70.49 | 6.57 | (0.16) | (31.22) | 4.25 | 14.68 |
| Closing cash | 198 | 208 | 143 | 20.90 | 138 | 365 | 155 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +11.5% | -2.5% | -3.8% | +1.5% | +11.0% | +3.8% | - |
| EBITDA growth | +27.6% | -12.7% | +2.2% | -6.5% | -59.1% | +3.1% | - |
| PBT growth | +33.8% | -24.5% | -3.6% | -15.0% | -61.0% | +7.2% | +58.6% |
| Net income growth | +45.0% | -25.3% | -3.5% | -20.6% | -60.3% | +23.1% | - |
| Revenue CAGR (3Y) | +1.5% | -1.6% | +2.7% | +5.4% | +9.0% | +26.0% | +38.7% |
| EBITDA CAGR (3Y) | +4.4% | -5.9% | -26.9% | -26.7% | -16.1% | +70.4% | +77.7% |
| Profitability & leverage | |||||||
| Net income margin | +5.9% | +4.9% | +6.4% | +6.3% | +7.6% | +22.6% | +19.1% |
| Return on capital employed | +10.6% | +8.8% | +12.3% | +13.6% | +17.1% | +53.8% | +67.5% |
| Return on net worth | +7.9% | +6.1% | +8.7% | +9.7% | +12.5% | +42.9% | +56.1% |
| Debt / equity | 0.07 | 0.05 | 0.04 | 0.04 | 0.02 | 0.03 | 0.27 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.15 |
| Interest cover | 8.19 | 11.33 | 9.55 | 9.13 | 4.16 | 1.05 | 3.89 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.46 | 1.50 | 1.91 | 2.52 | 3.04 | 3.09 | 3.44 |
| Inventory turnover | 6.34 | 5.29 | 5.68 | 6.03 | 6.20 | 8.15 | 10.07 |
| Debtors turnover | 4.15 | 4.22 | 4.37 | 4.55 | 5.67 | 6.87 | 8.03 |
| EPS (₹) | 4.69 | 3.44 | 23.07 | 23.84 | 28.22 | 75.72 | 63.51 |
| Dividend per share (₹) | 1.00 | 0.80 | 5.00 | 4.00 | 4.00 | 6.00 | 3.00 |
| Book value per share (₹) | 61.26 | 57.48 | 274.46 | 256.61 | 236.80 | 214.69 | 141.36 |
To see the full year-wise statements and ratios of Iol Chemicals and Pharmaceuticals Limited, buy the company report.
Board of directors of Iol Chemicals and Pharmaceuticals Limited
Iol Chemicals and Pharmaceuticals has 8 current directors and 21 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Harpal Singh Also directs: Success Steps Private Limited | Director | 06 Feb 2019 | 7 Years 9 Months | Current |
| Rajender Mohan Malla | Director | 06 Feb 2019 | 7 Years 9 Months | Current |
| Varinder Gupta Also directs: Iol Speciality Chemicals Limited, Mayadevi Polycot Limited, NM Merchantiles Limited and 1 more | Managing Director | 13 Nov 1986 | 39 Years 11 Months | Current |
| Vikas Gupta Also directs: Iol Speciality Chemicals Limited, Mayadevi Polycot Limited, NM Merchantiles Limited and 1 more | Whole-Time Director | 29 May 2015 | 11 Years 5 Months | Current |
| Kushal Kumar Rana | Whole-Time Director | 04 Jun 2021 | 5 Years 5 Months | Current |
| Sharad Tyagi Also directs: Procter & Gamble Health Limited, 34East Labs Private Limited | Director | 30 May 2022 | 4 Years 5 Months | Current |
Showing 6 of 8 current directors. View all directors
Peer comparison
Iol Chemicals and Pharmaceuticals Limited is compared with the 3 companies closest to it by revenue in the Chemicals industry (API Manufacturers, Pharmaceuticals, Specialty Chemicals), with the same principal business activity (manufacture of chemicals and chemical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Fine Organic Industries Limited | ₹2,366.75 Cr (FY 2025) | 8.0% | Mumbai, Maharashtra, India | |||
| Iol Chemicals and Pharmaceuticals Limitedthis company | ₹2,319.06 Cr (FY 2026) | ₹146.58 Cr | 6.3% | 11.5% | 2,778 | Barnala, Punjab, India |
| Vinati Organics Limited | ₹2,292.48 Cr (FY 2025) | 18.0% | Dist-Raigad, Maharashtra, India | |||
| Rossari Biotech Limited | ₹2,084.3 Cr (FY 2025) | 13.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Iol Chemicals and Pharmaceuticals Limited, buy the company report.
Auditor
Iol Chemicals and Pharmaceuticals Limited is audited by Ashwani & Associates for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Ashwani & Associates | FY 2025 | 000497N |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 62.30%, foreign institutional investors hold 4.90%, domestic institutional investors hold 0.40% and retail and other public shareholders hold 32.40%.
Sep 2026
QUARTER
62.30% Promoters
0.40% DII (Domestic Institutional)
4.90% FII (Foreign Institutional)
32.40% Retail & Others
Promoter holding - history
Now 62.30% · Sep 2026High 62.30% · Sep 2026Low 52.60% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 62.30% | 57.50% | 52.60% | 52.60% |
| Public | 37.70% | 42.50% | 47.40% | 47.40% |
Charges & borrowings
Open charges
₹700 Cr
Satisfied charges
₹1,487.01 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 21 Jun 2016 | 100037862 | Others | ₹700 Cr | Open | |
| 31 May 2016 | 100034269 | Others | ₹15 Cr | Satisfied | |
| 23 Mar 2015 | 10559118 | Others | ₹30.71 Cr | Satisfied | |
| 31 Dec 2014 | 10544515 | Punjab National Bank | ₹65.12 Cr | Satisfied | |
| 30 Jun 2014 | 10509239 | Punjab National Bank | ₹162.4 Cr | Satisfied |
To see the full charge records of Iol Chemicals and Pharmaceuticals Limited, buy the company report.
Total charge records: 57 View all charges
Deals & funding
Iol Chemicals and Pharmaceuticals Limited has 105 deals on record (70 market trades, 24 funding rounds, 11 secondary share transfers), with disclosed funding of ₹238.16 Cr; the latest was in July 2026.
Total deals
105
Market trades
70
Funding rounds
24
Secondary share transfers
11
Disclosed funding
₹238.16 Cr
Deals on record (5 of 105)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jul 2026 | Market trade | ₹89.42 Cr | Buyer: Microcurves Trading Private Limited , Qe Securities LLP , Hrti Private Limited Seller: Hrti Private Limited , Microcurves Trading Private Limited , Qe Securities LLP |
| Sep 2025 | Market trade | ₹154.34 Cr | Buyer: Graviton Research Capital LLP , Qe Securities LLP , Musigma Securities Seller: Graviton Research Capital LLP , Qe Securities LLP , Hrti Private Limited |
| Jul 2025 | Market trade | ₹16.56 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Dec 2024 | Market trade | ₹23.32 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Sep 2024 | Market trade | ₹68.51 Cr | Buyer: Graviton Research Capital LLP , Hrti Private Limited , Qe Securities LLP Seller: Graviton Research Capital LLP , Hrti Private Limited , Qe Securities LLP |
To see the full deal history of Iol Chemicals and Pharmaceuticals Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Iol Chemicals and Pharmaceuticals Limited has 76 court cases on record: 31 filed by Iol Chemicals and Pharmaceuticals, 46 filed against it. 14 cases are pending and 62 are disposed.
Total cases
76
Filed by the company
31
Filed against the company
46
Pending
14
Disposed
62
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 36 | 20 | 7 |
| High courts | 33 | 22 | 5 |
| Supreme Court | 6 | 4 | 2 |
| NCLT | 1 | 0 | 0 |
Cases on record (5 of 76)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Ludhiana, Punjab | Commercial suit | Filed by the company against Affine Formulations Ltd | Pending |
| District court, Ludhiana, Punjab | Commercial suit | Filed by the company against Delius Pharmaceuticals Private Limited | Pending |
| District court, Ludhiana, Punjab | Commercial suit | Filed by the company against Vip Pharmaceuticals Pvt Ltd | Pending |
| District court, Ludhiana, Punjab | Commercial suit | Filed by the company against Prizam Alliance Pvt Ltd | Pending |
| High Court of Punjab and Haryana | Appeal | Filed against the company by Flowlink Industries Pvt Ltd | Pending |
To see the full case history of Iol Chemicals and Pharmaceuticals Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Iol Chemicals and Pharmaceuticals Limited was last rated by Care on 06 Jul 2026.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 06 Jul 2026 |
To see the full credit ratings and regulatory alerts of Iol Chemicals and Pharmaceuticals Limited, buy the company report.
MSME payment delays
Iol Chemicals and Pharmaceuticals Limited has 11 MSME Form 1 returns on record between 2019 and 2024, listing 280 overdue payments to 65 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 65)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Ink IT Solutions and Consulting Private Limited | |||
| Alpha Engineering and Systems Private Limited | |||
| Del-Tech Instruments Private Limited | |||
| an individual supplier |
To see the full MSME payment records of Iol Chemicals and Pharmaceuticals Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Iol Chemicals and Pharmaceuticals has 3 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
3
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Iol Speciality Chemicals Limited | U24290PB2022PLC056275 | |
| Iol Life Sciences Limited | U24299PB2022PLC056233 | |
| Iol-Foundation | U85300PB2022NPL055428 |
To see the full group structure of Iol Chemicals and Pharmaceuticals Limited, buy the company report.
Employees & EPFO
Iol Chemicals and Pharmaceuticals Limited has a workforce of 2,778 employees on its EPFO records as of Apr 01, 2024, across 1 active EPFO establishment.
Employee count
2,778
Active EPFO establishments
1
Employee growth
3.62%
GST
Iol Chemicals and Pharmaceuticals has 5 GST registrations: 3 active and 2 cancelled or inactive.
Total GSTINs
5
Active
3
Cancelled / inactive
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 03AABCI1842A1ZF | Punjab | Active | 01 Jul 2017 |
| 24AABCI1842A1ZB | Gujarat | Active | 27 Nov 2017 |
| 06AABCI1842A2Z8 | Haryana | Active | 07 Sep 2022 |
To see the full GST registrations and return filing status of Iol Chemicals and Pharmaceuticals Limited, buy the company report.
Recent activity
Iol Chemicals and Pharmaceuticals Limited has 43 board changes on record since 1986: 26 appointments and 17 cessations. The latest: Rajni Jha was appointed as Director on 28 Oct 2024.
Filing
Iol Chemicals And Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Chandigarh.
AGM
Iol Chemicals And Pharmaceuticals Limited last Annual general meeting of members was held on 22 Aug 2025 as per latest MCA records.
Appointed
Rajni Jha was appointed as Director.
Charges
A charge with Others of Rs. 700.00 Cr registered on 21 Jun 2016 with Charge ID 100037862 was modified on 18 Sep 2024.
Ceased
Sandhya Mehta ceased to be Director.
Appointed
Abhiraj Gupta was appointed as Whole-Time Director.
Ceased
Sanjay Chaturvedi ceased to be Whole-Time Director.
Appointed
Sharad Tyagi was appointed as Director.
Appointed
Kushal Kumar Rana was appointed as Whole-Time Director.
Ceased
Vijay Garg ceased to be Whole-Time Director.
Appointed
Sanjay Chaturvedi was appointed as Whole-Time Director.
Charges
A charge registered on 31 May 2016 via Charge ID 100034269 with Others was fully satisfied on 20 Jun 2020.
187 earlier events are in the company report.
News
IOL CP: Increases FY27 Guidance Significantly: Revenue Growth Target Raised To Over 25% From 15%; Capex Guidance Increased To ₹250 Crore From ₹200 Crore.
IOLCP: Q2 REVENUE 7.95B RUPEES VS 5.67B (YOY)
IOLCP: Q2 SL NET PROFIT 650M RUPEES VS 300M (YOY)
IOLCP: Q2 EBITDA 1.1B RUPEES VS 565M (YOY); Q2 EBITDA MARGIN 13.73% VS 9.97% (YOY)
IOL Chemicals And Pharmaceuticals Limited: Obtains Certificate Of Suitability From EDQM For Fenofibrate - Process II, Boosting Regulatory Portfolio And Aiding Supply In Regulated Markets.
Frequently asked questions
Iol Chemicals and Pharmaceuticals is an active public limited company based in Barnala, Punjab, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 29 September 1986 (40+ years old) and is registered under CIN L24116PB1986PLC007030. Listed on BSE: 524164 and NSE: IOLCP.
Iol Chemicals and Pharmaceuticals reported revenue of ₹2,319.06 Cr for FY 2025-26 (up 11.5% YoY) based on consolidated financials.
Iol Chemicals and Pharmaceuticals has 8 current directors:
- Varinder Gupta - Managing Director
- Vikas Gupta - Whole-Time Director
- Kushal Kumar Rana - Whole-Time Director
- Abhiraj Gupta - Whole-Time Director
- Harpal Singh - Director
- Rajender Mohan Malla - Director
- Sharad Tyagi - Director
- Rajni Jha - Director
The latest financial statements of Iol Chemicals and Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 22 August 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Iol Chemicals and Pharmaceuticals is 03AABCI1842A1ZF, registered in Punjab. The company has 5 GST registrations in all, of which 3 are active and 2 are cancelled or inactive. Other active GSTINs include 24AABCI1842A1ZB (Gujarat), 06AABCI1842A2Z8 (Haryana).
The CIN (Corporate Identification Number) of Iol Chemicals and Pharmaceuticals is L24116PB1986PLC007030. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Iol Chemicals and Pharmaceuticals is a listed company as per MCA records. Its shares are listed on both BSE (code: 524164) and NSE (symbol: IOLCP).
Iol Chemicals and Pharmaceuticals has 76 court cases on record: 31 filed by the company and 46 filed against it. 14 are pending. Most are in the district courts.
Iol Chemicals and Pharmaceuticals was incorporated on 29 September 1986, making it 40+ years old. It is registered with the Registrar of Companies, Chandigarh.
Iol Chemicals and Pharmaceuticals has 105 deals on record (70 market trades, 24 funding rounds, 11 secondary share transfers), with disclosed funding of ₹238.16 Cr; the latest was in July 2026.
The peers of Iol Chemicals and Pharmaceuticals by revenue are Fine Organic Industries Limited, Vinati Organics Limited, Rossari Biotech Limited, all in the Chemicals industry (API Manufacturers, Pharmaceuticals, Specialty Chemicals), with the same principal business activity (manufacture of chemicals and chemical products).
Rajni Jha was appointed as Director on 28 Oct 2024. Sandhya Mehta ceased to be Director on 21 Aug 2024. Abhiraj Gupta was appointed as Whole-Time Director on 03 Apr 2023. Iol Chemicals and Pharmaceuticals has 43 board changes on record in total.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages